Anavex Announces Exceeding of Enrollment Target for the ANAVEX®2-73 (blarcamesine) EXCELLENCE Phase 2/3 Rett Syndrome Clinical Trial
Anavex Life Sciences Corp., a clinical-stage biopharmaceutical company, announced that 92 patients with Rett syndrome have been enrolled in the ANAVEX®2-73 (blarcamesine) EXCELLENCE Phase 2/3 study in ...